Navigation Links
GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results
Date:2/25/2011

dy immune responses. Stimulation of both T cells and antibodies differentiates the GeoVax vaccine from many other vaccine candidates. GeoVax's DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. These particles contain proteins that mimic more than half of the components of the HIV virus, but cannot cause AIDS. This multi-protein approach is designed to elicit a broad multi-target protective T cell response. The Env protein is designed to elicit a protective antibody response against the natural form of the virus envelope glycoprotein as well as protective T cells.  GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as the vaccines' safety.

About HIV/AIDSAIDS is an epidemic that can affect anyone, regardless of race, gender, age or sexual orientation. 33 million people are currently infected globally and it is estimated that there will be 2.5 million new infections this year. Since the beginning of the epidemic, over a million people in the U.S. have contracted the virus. Every 9 1/2 minutes, someone in the U.S. is infected with AIDS. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in North America. Globally, most infections involve subtypes AG, B, and C.  GeoVax vaccines are currently designed to function against clade B.  In 2008
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
6. GeoVax to Present at the BIO CEO & Investor Conference 2009
7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
10. GeoVax Labs, Inc. Announces First Quarter Financial Results
11. GeoVax to Exhibit at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  Pfenex Inc. (NYSE MKT: PFNX), ... of high-value and difficult to manufacture proteins including ... reported financial results for the second quarter ended ... completion of our initial public offering, we have ... product candidates, derived from our proprietary protein expression ...
(Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 According to a ... Market” the global orthobiologics market was valued at USD 3,754.6 ... worth USD 5,519.9million in 2019at a CAGR of 5.9% from ... 50 years and above is afflicted by bone and joint ... the year 2020. This has and will continue to increase ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... Amarin Corporation plc,(NASDAQ: AMRN ) ("Amarin" or ... of Amarin, will present at the Acumen,BioFin Rodman & ... 12 noon Eastern time. The conference will be held ... New York. The presentation will be simultaneously webcast ...
... NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company ... that it is scheduled to present,on Monday, November ... Annual,Healthcare Conference and on Tuesday, November 6, 2007 ... Healthcare Conference. Anthony DiTonno,President and Chief Executive Officer, ...
... October 31 Revotar,Biopharmaceuticals AG., today announced first ... IIa pilot study in 14 patients with,stable COPD ... mg of Bimosiamose,twice a day. The study was ... Prof. Witt and the Respiratory Institute Wiesbaden, Dr.,Beeh. ...
Cached Biology Technology:Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference 2Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference 3NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3Revotar Reports First Positive Clinical Results From Phase IIa Study in COPD 2
(Date:8/29/2014)... Researchers at UC Davis have made some surprising ... infection. Studying simian immunodeficiency virus (SIV), the team ... Paneth cells are early responders to viral invasion ... producing a cytokine called interleukin-1 beta (IL-1β). ... IL-1β causes breakdown of the gut epithelium that ...
(Date:8/29/2014)... (Aug. 29, 2014) Scientists at the Barshop Institute ... of Medicine at the UT Health Science Center at ... the tissues of the longest-lived rodent, the naked mole ... the cells of naked mole rats protects and alters ... damaged and obsolete proteins. , The factor also protects ...
(Date:8/29/2014)... been known about what genetic changes transform wild animals ... of whom is a University of Montana assistant professor, ... the development of the brain and the nervous system ... published Aug. 28 in Science and gives ... http://www.sciencemag.org/ ., The domestication of animals and plants, ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... too short, then you,re not alone. A team of scientists from Texas ... long life and they made important discoveries that bring longer life spans ... of The FASEB Journal ( http://www.fasebj.org ), describes how scientists ... the process discovered a new metabolic state correlating with long life. ...
... of two studies published in the current issue of ... cerebral ischemia and ischemic stroke in rats may significantly ... found that administering bone marrow stromal stem cells (MSC) ... which coincided with activation of microglia and new blood ...
... This release is available in German . , ... reliable testing of HIV inhibitors. This system was developed under ... Virology. At the heart of the system are cultured human ... that signal HIV infection by producing a red fluorescent protein. ...
Cached Biology News:Longevity breakthrough: The metabolic state of mitochondria controls life span 2Stroke research takes 2 steps forward 2Stroke research takes 2 steps forward 3A powerful new technology to identify HIV inhibitors 2
Request Info...
...
...
... are available in two product models - the ... models is that the 6000AT+ includes a membrane ... aerosol for improved detection limits and reduced oxides. ... range of elements by 10-40 times. Note that ...
Biology Products: